Fingertip Pulse Oximeter A310 is a non-invasive device intended for spot checking of functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR). This portable device is indicated for use in adult patients in hospitals.

Device Description

Fingertip Pulse Oximeter A310 is a battery powered device intended for use in measuring and displaying functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR). The Finger Pulse Oximeter works by applying a sensor to a pulsating arteriolar vascular bed. The sensor contains a dual light source and photo detector. The one wavelength of light source is 660 nm, which is red light; the other is 940 nm, which is Infrared light. Skin, bone, tissue, and venous vessels normally absorb a constant amount of light over time. The photodetector in finger sensor collects and converts the light into electronic signal which is proportional to the light intensity. The arteriolar bed normally pulsates and absorbs variable amounts of light during systole and diastole, as blood volume increases and decreases. The ratio of light absorbed at systole and diastole is translated into an oxygen saturation measurement. This measurement is referred to as SpO2. This equipment mainly composed of PCB board, On/Off button, mode button, OLED screen, battery compartment, and plastic shell. The device is a spot-check pulse oximeter and does not include alarms. The device does not support the measurement in the condition of low perfusion. The device is not intended for life-supporting or life-sustaining. The device is reusable and does not need sterilization.

AI/ML Overview

Here's a breakdown of the acceptance criteria and study details for the Fingertip Pulse Oximeter A310, based on the provided document:

1. Acceptance Criteria and Reported Device Performance

Parameter	Acceptance Criteria (Specification)	Reported Device Performance (RMS value)
SpO2 Accuracy (70-100%)	±3%	2.21%
SpO2 Accuracy (70-<80%)	N/A (implied within 70-100%)	2.42%
SpO2 Accuracy (80-<90%)	N/A (implied within 70-100%)	1.58%
SpO2 Accuracy (90-100%)	N/A (implied within 70-100%)	2.80%
PR Accuracy (30-99 bpm)	±2 bpm	Complies with declaration
PR Accuracy (100-235 bpm)	2%	Complies with declaration

Note: The document explicitly states the SpO2 accuracy is ±3% for the range 70-100%, and the reported RMS values are all less than 3%, thus meeting this criterion. For Pulse Rate (PR) accuracy, the document states "complies with the declaration of specification at the normal condition," implying that the device met the stated accuracies of ±2 bpm (30-99 bpm) and 2% (100-235 bpm).

2. Sample Size Used for the Test Set and Data Provenance

Sample Size for Test Set: 12 healthy adult volunteers (8 men, 4 women).
Data Provenance: The study was a clinical evaluation conducted on human subjects, implying a prospective study design. The country of origin is not explicitly stated, but the company is based in Milpitas, California, USA, suggesting the study likely took place in the USA or under US regulatory standards.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

The ground truth for SpO2 was established using a laboratory CO-Oximeter on blood samples. While this is a highly accurate method, the document does not specify if human experts (e.g., lab technicians, doctors) were involved in interpreting or validating the CO-Oximeter results, or their specific qualifications if they were. The CO-Oximeter itself serves as the 'expert' in this context.

4. Adjudication Method for the Test Set

Not applicable. The ground truth for SpO2 was derived directly from blood samples analyzed by a CO-Oximeter, which provides objective measurements. There was no mention of multiple human readers or a consensus process for the SpO2 ground truth.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, an MRMC comparative effectiveness study was not conducted. This study focused on the standalone accuracy of the device against a CO-Oximeter, not on how human readers' performance might improve with or without AI assistance.

6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done

Yes, a standalone performance study was conducted. The clinical evaluation directly compared the SpO2 readings from the Fingertip Pulse Oximeter A310 (algorithm only, as it's a non-invasive device for automated measurement) against the ground truth established by a laboratory CO-Oximeter.

7. The Type of Ground Truth Used

The type of ground truth used for SpO2 accuracy was direct physiological measurement via a laboratory CO-Oximeter on arterial blood samples (SaO2). This is a highly accurate and objective form of physiological reference.

8. The Sample Size for the Training Set

The document does not mention a training set or any details about a training process for the device's algorithm. For pulse oximeters, the core technology relies on established physical principles of light absorption by oxygenated and deoxygenated hemoglobin, rather than machine learning models that require explicit training sets. The "accuracy" is typically about calibration and hardware/software performance within these physical limits.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as no training set was mentioned.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features a stylized caduceus-like symbol with three figures in profile, representing health and human services. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

November 22, 2016

AMEMO INC. Hua Xie CEO 1154 Cadillac Court Milpitas. California 95035

Re: K153021

Trade/Device Name: Fingertip Pulse Oximeter A310 Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: Class II Product Code: DQA Dated: November 14, 2016 Received: November 14, 2016

Dear Hua Xie:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

Tejashri Purohit-Sheth, M.D.

Tejashri Purohit-Sheth, M.D. Clinical Deputy Director DAGRID/ODE/CDRH FOR

Tina Kiang, Ph.D. Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K153021

Device Name Fingertip Pulse Oximeter

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW!

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

AMEMO INC 1154 Cadillac Court Milpitas CA 95035 USA

Section III 510(K) Summary

Date: 2016-11-17

Sponsor:

AMEMO INC

1154 Cadillac Court Milpitas CA 95035 USA Contact person: Mr. Hua Xie Email: Raymond691116@gmail.com

Proposed Device:

Model	Name
A310	Fingertip Pulse Oximeter

Trade Name: Fingertip Pulse Oximeter

Common Name: Fingertip Pulse Oximeter

Product Classification: DQA; 870.2700; Class II

Classification Panel: Anesthesiology

Predicate Device: MD300C1 Fingertip Pulse Oximeter (K093757)

Indications for use:

Device description:

Fingertip Pulse Oximeter A310 is a battery powered device intended for use in

{4}------------------------------------------------

1154 Cadillac Court Milpitas CA 95035 USA measuring and displaying functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR).

The Finger Pulse Oximeter works by applying a sensor to a pulsating arteriolar vascular bed. The sensor contains a dual light source and photo detector. The one wavelength of light source is 660 nm, which is red light; the other is 940 nm, which is Infrared light. Skin, bone, tissue, and venous vessels normally absorb a constant amount of light over time. The photodetector in finger sensor collects and converts the light into electronic signal which is proportional to the light intensity. The arteriolar bed normally pulsates and absorbs variable amounts of light during systole and diastole, as blood volume increases and decreases. The ratio of light absorbed at systole and diastole is translated into an oxygen saturation measurement. This measurement is referred to as SpO2.

This equipment mainly composed of PCB board, On/Off button, mode button, OLED screen, battery compartment, and plastic shell.

The device is a spot-check pulse oximeter and does not include alarms.

The device does not support the measurement in the condition of low perfusion.

The device is not intended for life-supporting or life-sustaining.

The device is reusable and does not need sterilization.

{5}------------------------------------------------

1154 Cadillac Court Milpitas CA 95035 USA

Comparison list of the technological characteristics

Comparison Items	Applicant Device	Predicate Device (K093757)	Remark
Indications for use	Fingertip Pulse Oximeter A310 is anon-invasive device intended for spotchecking of functional oxygen saturationof arterial hemoglobin (SpO2) and pulserate (PR). This portable device isindicated for use in adult patients inhospitals	Fingertip Pulse Oximeter MD300C1 is aportable non-invasive, spot-check,oxygen saturation of arterial hemoglobin(SpO2) and pulse rate of adult andpediatric patient at home, and hospital(including clinical use ininternist/surgery, Anesthesia, intensivecare and etc). Not for continuouslymonitoring	Different①
Principle	The device displays numerical values forfunctional oxygen saturation of arterialhemoglobin (SpO2) and pulse rate bymeasuring the absorption of red andinfrared (IR) light passing throughperfused tissue.Changes in the absorption caused bythe pulsation of blood in the vascularbed are used to determine oxygensaturation and pulse rate.	The device displays numerical valuesfor functional oxygen saturation ofarterial hemoglobin (SpO2) and pulserate by measuring the absorption of redand infrared (IR) light passing throughperfused tissue.Changes in the absorption caused bythe pulsation of blood in the vascularbed are used to determine oxygensaturation and pulse rate.	Same
Specifications	LED wavelength	Red= 660 nm; Infrared=905nm	Red= 660 nm; Infrared=940nm	Different②
	Power source	2 AAA alkaline batteries.	2 AAA alkaline batteries.	Same
Testing	Display data	SPO2%; PR	SPO2%; PR	Same
	SpO2 MeasuringRange	0%-100%	0%-100%	Same
	SpO2 Resolution	1%	1%	Same
	SpO2 Accuracy	70~100%, ±3%;0-69%, unspecified;	70~100%, ±3%;0-69%, unspecified;	Same
	PR MeasuringRange	30-235BPM.	30-235BPM	Same
	PR Resolution	1 bpm	1 bpm	Same
	PR Accuracy	± 2 bpm (30-99bmp)2% (100-235bmp)	± 2 bpm (30-99bmp)2% (100-235bmp)	Same
	Biocompatibility	ISO 10993-5 and ISO 10993-10	ISO 10993-5 and ISO 10993-10	Same
	Electrical Safety	IEC 60601-1IEC 60601-1-11	IEC 60601-1IEC 60601-1-11	Same
	ElectromagneticCompatibility	IEC 60601-1-2	IEC 60601-1-2	Same
	Performance	ISO 80601-2-61	ISO 9919	Different③

{6}------------------------------------------------

1154 Cadillac Court Milpitas CA 95035 USA

{7}------------------------------------------------

1154 Cadillac Court Milpitas CA 95035 USA

[Discussion]

The proposed device has the same application site, performance testing, and accuracy as the differences are

1. The predicate device is intended for both adult and pediatric patients in hospital and home environments, however Oximeter A310 is intended only for adult in hospital environments. Both applicable population and environment of A310 are smaller than the predicate, which will not raise different questions of safety or effectiveness compared to the predicate device. All A310's indications for use is Substantially Equivalent (SE) to the predicate device in its declared scope.
1. Infrared LED Wavelength of Oximeter A310 is 905nm, and predicate's wavelength is 940nm. These two wavelengths are both adopted widely in measurement of SPO2. This difference will affect the performance of the device, especially the accuracy. We conducted the ISO 80601-2-61 test to verify the performance and electrical safety of Oximeter A310, and the clinical evaluation to validate the accuracy of measurement. The clinical evaluation result shows that A310's accuracy complies with the requirement defined in the standard ISO 80601-2-61. All validation demonstrates that Oximeter A310 is substantially equivalent to the predicate device.
1. Application of the performance standard is different. The predicate device uses the ISO 9919 to demonstrate the performance. However, ISO 9919 has been withdrawn, and ISO 80601-2-61 is the newest international performance standard of oximeter, and state-of-the oximeter. And, ISO 80601-2-61 is also the Recognized Consensus Standards of FDA.

{8}------------------------------------------------

1154 Cadillac Court Milpitas CA 95035 USA

Non-clinical testing summary:

The Fingertip Pulse Oximeter A310 was subjected to bench testing. The following non-clinical testing was performed to demonstrate substantial equivalence of A310 with its predicate. The test results demonstrated that the proposed device complies with the following standards and requirements:

IEC 60601-1: Medical Electrical Equipment - Part 1: General Requirements for Basic Safety and essential performance

IEC 60601-1-2: Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic compatibility - Requirements and tests

ISO 80601-2-61: Medical electrical equipment - Particular requirements for the basic safety and essential performance of pulse oximeter equipment for medical use.

IEC 60601-1-11: Medical electrical equipment -- Part 1-11: General requirements for basic safety and essential performance -- Collateral standard: Requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment

FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices.

FDA Guidance for Pulse Oximeters - Premarket Notification Submissions [510(k)s]

ISO 10993-5: Biological evaluation of medical devices -- Part 5: Tests for in vitro cytotoxicity

ISO 10993-10: Biological evaluation of medical devices -- Part 10: Tests for irritation and skin sensitization

Pulse Rate Accuracy testing has been performed by referring to the SpO2 simulator. Pulse rate accuracy was stated as the root-mean-square difference between paired pulse date recorded with A310 and simulator. The testing procedure and results are included in the report A310 Fingertip Pulse Rate Accuracy Test Report, which

{9}------------------------------------------------

1154 Cadillac Court Milpitas CA 95035 USA

includes the results of PR measurement range, resolution, and measurement accuracy. The report demonstrates that the PR accuracy complies with the declaration of specification at the normal condition.

The testing to verify the performance after simulated lifetime was conducted. The testing conducted included 1424 cycles of cleaning of the device according to the description in the operation manual. After the cycles of cleaning, the accuracy testing of SpO2 and PR was performed by referring to the SpO2 simulator. The testing result demonstrates that the device continues to perform within specifications after a simulated lifetime of use.

Clinical testing summary

The functional oxygen saturation (SpO2) measurement has been validated in accordance with ISO 80601-2-61. The clinical testing was completed on a total of 12 healthy adult volunteers (8 man and 4 women) with light to dark skin pigmentations in the range of 70% to 100% against a laboratory CO-Oximeter. The subjects include 6 people with medium skin, 1 with light skin, and 5 with dark skin pigmentation. Total 555 data points were sampled for analysis.

The measured arterial hemoglobin saturation value (SpO2) of the proposed device was compared with arterial hemoglobin oxygen (SaO2) value, determined from blood samples with a CO-oximeter. The accuracy of the device is in comparison with the CO-oximeter samples measured over the SpO2 range 70%-100%.

Accuracy data was calculated using the root-mean-squared (Arms value) for all subjects, per ISO 80601-2-61, the result showed that the error is far less than the scope specified in the standard; and the Agreement between Methods of Measurement with Multiple Observations per each subject was analyzed with the Bland and Altman statistics, the analysis demonstrated that the vast majority of data is within ±95% limit of agreement.

The SpO2 accuracy result showed that the root-mean-square (Arms) value of the Fingertip Pulse Oximeter is ±3% with the saturations from 70% to 100%. The following is the summary of the testing results:

Items	70-100	70-<80	80-<90	90-100
#pts	555	192	237	126
Bias	0.40	0.98	0.41	1.06
RMS	2.21	2.42	1.58	2.80

{10}------------------------------------------------

1154 Cadillac Court Milpitas CA 95035 USA

In addition, there were no reported adverse effects during these investigations.

Conclusion:

The Fingertip Pulse Oximeter A310 has the same intended use, the same technology as the predicate device. Thus we conclude the subject device to be Substantially Equivalent to the predicate device.

Regulation Number and Section

§ 870.2700 Oximeter.

(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).